1. Home
  2. Resources
  3. Featured Solutions
  4. Universal Therapeutic Conjugate (UTC) Development Solution
  5. Antibody-Antibiotic Conjugate (AAC) Development Solution
  6. Bacterial Infection related Antibody Discovery

Antibody Discovery Services for Bacterial Targets: AAC Development

The escalating threat of antimicrobial resistance demands a paradigm shift from broad-spectrum antibiotics to targeted biotherapeutics. Creative Biolabs offers specialized antibody discovery services for bacterial infection, designed to isolate high-affinity monoclonal antibodies against clinically relevant bacterial targets. Our platforms are optimized for the pre-clinical development of antibody-antibiotic conjugates (AACs), enabling precise targeting of pathogens such as Staphylococcus aureus, Salmonella, and Pseudomonas aeruginosa. From target identification and antigen preparation to antibody humanization and specificity validation, we provide a seamless pipeline that transforms complex immunological challenges into development-ready therapeutic candidates.

Request Discovery Consultation

Comprehensive Antibody Discovery Services for Bacterial Targets

β-GlcNAc-WTA Specific Antibody Discovery
Staphylococcus aureus related Antibody Discoveryg
Salmonella related Antibody Discovery
Escherichia coli related Antibody Discovery

Addressing Antimicrobial Resistance Through Targeted Antibody Discovery

The global rise of multidrug-resistant bacterial pathogens has rendered conventional antibiotic therapies increasingly ineffective. Antibody-antibiotic conjugates represent a promising therapeutic modality that combines the pathogen-specific targeting capability of monoclonal antibodies with the potent bactericidal activity of antibiotic payloads. Our antibody discovery services are strategically designed to support pre-clinical AAC development by identifying antibodies that recognize conserved bacterial surface antigens with high specificity and affinity.

Core Objectives of Our Bacterial Antibody Discovery Platform

We focus on delivering development-ready antibody candidates through a rigorously validated discovery pipeline:

  • • Target-Specific Antigen Design: Selection and preparation of bacterial surface proteins, virulence factors, and cell-wall components that represent viable therapeutic targets while minimizing cross-reactivity with commensal flora.
  • • High-Affinity Antibody Isolation: Utilization of phage display, hybridoma technology, and single B cell screening to isolate antibodies with sub-nanomolar binding affinities against clinically relevant bacterial epitopes.
  • • Pre-clinical Characterization: Comprehensive in vitro validation including binding kinetics, epitope mapping, cross-reactivity profiling, and preliminary stability assessment to ensure candidate suitability for conjugation.

Integrated Antibody Discovery Service Units

Our service architecture is organized into four specialized units, each addressing critical phases of bacterial-target antibody discovery from antigen preparation through candidate validation.

Bacterial Antigen Design & Preparation

Successful antibody discovery begins with rational antigen selection. We identify and produce immunogenic bacterial targets that elicit therapeutically relevant antibody responses while avoiding tolerance mechanisms.

Target Categories
  • • Cell Surface Proteins: Cell-wall anchored proteins, outer membrane proteins, and surface-exposed virulence factors from Gram-positive and Gram-negative pathogens.
  • • Secreted Toxins: Alpha-hemolysin, Panton-Valentine leukocidin, and other exotoxins that contribute to pathogenesis.
  • • Capsular Polysaccharides: Highly conserved serotype-independent epitopes suitable for broad-spectrum therapeutic applications.
Expression Systems
We employ Escherichia coli, Pichia pastoris, and mammalian expression platforms to produce correctly folded recombinant antigens with native conformational epitopes. Lipopolysaccharide removal and endotoxin control are implemented to ensure immunological compatibility.

Antibody Discovery & High-Throughput Screening

We deploy complementary discovery technologies to maximize the probability of identifying rare antibodies with optimal developability profiles for AAC applications.

Discovery Platforms
  • • Phage Display: Naive and immune scFv/Fab libraries with diversities exceeding 1010 clones, enabling rapid isolation of fully human antibodies in vitro without immunization.
  • • Hybridoma Technology: Classical mouse and rat hybridoma generation with optimized immunization protocols using live-attenuated bacteria, purified antigens, or DNA vaccination.
  • • Single B Cell Screening: Microfluidics-enabled sorting of antigen-specific plasma cells directly from immunized donors, preserving native heavy-light chain pairing.
Screening Stringency
Discovery campaigns incorporate sequential counter-screening against human microbiome commensals, closely related non-pathogenic species, and mammalian cell lines to eliminate cross-reactive clones early in the selection process.

Antibody Engineering & Humanization

Raw discovery outputs require systematic optimization to ensure compatibility with human immune systems and AAC manufacturing requirements.

Engineering Services
  • • Complementarity-Determining Region Grafting: Preservation of antigen-binding affinity during conversion of murine antibodies to human frameworks.
  • • Framework Selection: Human germline framework selection optimized for expression yield, stability, and reduced immunogenicity risk.
  • • Developability Enhancement: Silencing of potential post-translational modification hotspots, removal of deamidation-prone sequences, and aggregation propensity reduction.
Conjugation Compatibility
Engineered cysteine or unnatural amino acid insertion for site-specific payload attachment, ensuring homogeneous drug-to-antibody ratios essential for AAC therapeutic index optimization.

Pre-clinical Validation & Characterization

Comprehensive biophysical and functional characterization ensures that antibody candidates meet the stringent quality standards required for transition to conjugation and in vivo efficacy studies.

Binding Characterization
  • • Surface Plasmon Resonance: Kinetic analysis of antigen binding with resolution of association and dissociation rate constants.
  • • Epitope Mapping: Peptide tiling, hydrogen-deuterium exchange mass spectrometry, and competitive binding assays to define precise epitope location.
  • • Cross-Reactivity Profiling: Testing against panels of clinical isolates, commensal strains, and human tissue samples.
Functional Assays
Opsonophagocytic killing assays, neutrophil recruitment assays, and toxin neutralization studies provide functional evidence of therapeutic mechanism. Stability under thermal, oxidative, and pH stress conditions is evaluated to predict manufacturability and shelf-life.

Antibody Discovery Workflow for Bacterial Infection Targets

Our standardized workflow integrates antigen design, immunological discovery, and rigorous characterization into a coherent pre-clinical development pathway.

Antibody Discovery Workflow for Bacterial Infection - From Target Selection to Pre-clinical Candidate

Step 1: Target Identification

Bioinformatic analysis of bacterial genomes and surface proteomes to identify conserved, surface-exposed, and immunogenic targets with low homology to human proteins. Literature and patent landscape review to ensure freedom to operate.

Step 2: Antigen Production

Cloning, expression, and purification of selected targets with endotoxin control and conformational validation. Generation of DNA vaccines or live-attenuated bacterial preparations for immunization.

Step 3: Discovery Campaign

Parallel execution of phage display panning, hybridoma fusion, or single B cell sorting depending on project requirements. Primary screening by ELISA and flow cytometry against live bacterial cells.

Step 4: Lead Optimization

Affinity maturation through CDR randomization, humanization, and developability engineering. Introduction of site-specific conjugation handles for AAC compatibility.

Step 5: Pre-clinical Validation

Comprehensive biophysical characterization, epitope mapping, functional assays, and stability studies. Generation of research cell banks and documentation for technology transfer.

Technology Platforms for Bacterial Antibody Discovery

Our technology portfolio spans established and emerging platforms, each selected to match the biological complexity of bacterial targets and the specific requirements of AAC development.

Phage Display Technology

High-diversity scFv and Fab libraries enable in vitro selection against challenging bacterial antigens, including toxins and membrane proteins that may be poorly immunogenic in vivo. The platform supports rapid turnaround and full human antibody generation without species restrictions.

Hybridoma Development

Classical hybridoma technology remains the gold standard for generating high-affinity murine antibodies against bacterial surface antigens. Our optimized immunization protocols using live bacteria and adjuvant formulations elicit robust immune responses even against poorly immunogenic targets.

Single B Cell Screening

Microfluidics-based single cell analysis captures native antibody pairs directly from antigen-specific B cells isolated from immunized animals or convalescent donors. This approach preserves the natural somatic hypermutation and pairing optimization that occurs in vivo.

FACS-Enabled Cell Sorting

High-throughput fluorescence-activated cell sorting allows direct screening of antibody libraries against live bacterial cells, enabling selection for conformation-specific epitopes and functional blocking activity in a native membrane context.

Research Insights in Anti-Bacterial Antibody Discovery

According to recent landmark studies, coupling high-throughput phage display platform technology with advanced sequencing is the gold standard for rapid therapeutic antibody discovery against antibiotic-resistant bacterial targets:

Case Study Highlights (Bacterial Target Discovery):

  • • Cell Surface Characterization: Interrogating the cell-wall landscape of pathogen genotypes (such as S. aureus or P. aeruginosa) via high-density phage display combined with Next-Generation Sequencing (NGS) allows deep mapping of conformation-specific, conserved cell-surface epitopes.
  • • High-Throughput Library Panning: Portable libraries of stable phages enable fast screen turnaround, identifying therapeutic antibodies that disrupt biofilm matrix proteins, outer-membrane channels, or block essential virulence factors.
  • • Site-Specific Conjugation Optimization: Utilizing novel bacterial enzymes (like transglutaminase with specific Q-tag substrates) enables homogeneous and site-specific payload attachment, avoiding steric hindrance at CDRs while maintaining high pathogen affinity and low system toxicity.

These advanced scientific methodologies facilitate the rapid translation of discovered binders into high-stability, highly selective antibody-antibiotic conjugates (AACs) ready for clinical trials.

Schematic of site-specific antibody-drug conjugate conjugation catalyzed by microbial transglutaminase.

Fig.1 PMicrobial transglutaminase-mediated site-specific ADC conjugation.3,4

Frequently Asked Questions About Bacterial Antibody Discovery

Q: What makes bacterial targets challenging for antibody discovery compared to traditional therapeutic targets?

A: Bacterial surface proteins are often embedded in complex cell wall structures, display high glycosylation variability, and share homology with human microbiome commensals. Additionally, many critical virulence factors are secreted toxins that may not be accessible to antibodies in systemic circulation. Our discovery pipeline addresses these challenges through live-cell screening, counter-selection against commensal panels, and strategic antigen selection focusing on surface-exposed conserved epitopes.

Q: How do you ensure that discovered antibodies are suitable for antibody-antibiotic conjugate development?

A: AAC-compatible antibodies require specific developability characteristics including appropriate surface exposed lysines or engineered cysteines for site-specific conjugation, stability under conjugation chemistry conditions, and preservation of antigen binding after payload attachment. We incorporate conjugation site analysis, forced degradation studies, and mock-conjugation assessments into our standard validation pipeline to ensure candidate suitability for subsequent AAC manufacturing.

Q: What is the typical timeline from target selection to validated pre-clinical antibody candidates?

A: A standard discovery campaign from antigen preparation through lead validation typically requires 6 to 9 months. Phage display campaigns offer the fastest turnaround at approximately 4 to 5 months for initial lead identification, while hybridoma programs require 6 to 8 months including immunization. Single B cell screening timelines fall between these ranges depending on donor availability. Humanization and developability optimization add an additional 2 to 3 months.

Q: Can you discover antibodies against biofilm-associated bacterial antigens?

A: Yes. Biofilm-associated infections present unique challenges because bacteria within biofilms express distinct antigenic profiles compared to planktonic cells. We offer specialized immunization protocols using biofilm-derived antigens, extracellular polymeric substance components, and stationary-phase bacterial preparations. Our screening platforms can select for antibodies that disrupt biofilm integrity or target metabolically dormant persister cells.

Q: What species of bacteria can your antibody discovery platforms target?

A: Our platforms are antigen-agnostic and have been validated against a broad spectrum of clinically relevant pathogens including Gram-positive organisms such as Staphylococcus aureus and Streptococcus pneumoniae, Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, as well as fastidious organisms. Both multidrug-resistant clinical isolates and reference strains can be accommodated.

Related Products

Anti-Bacterial Antibodies
Phage Display Libraries
Recombinant Bacterial Antigens

Related Resources

review
Reviews
Literature
Literature
Protocol
Protocol

References:
1. Zhao, Hui, et al. "Phage Display-Derived Peptides and Antibodies for Bacterial Infectious Diseases Therapy and Diagnosis." Molecules 28.6 (2023): 2621. 10.3390/molecules28062621
2. Bayat, Fereshteh, et al. "High throughput platform technology for rapid target identification in personalized phage therapy." Nature Communications 15 (2024): 5626. 10.1038/s41467-024-49710-2
3. El Alaoui, Meddy, et al. "Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase." Cell Death Discovery 10 (2024): 79. 10.1038/s41420-024-01845-3
4. Distributed under Open Access License CC BY 4.0, without modification.

For Research Use Only. NOT FOR CLINICAL USE.



Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Creative Biolabs quality assurance certification